Generic name
Granulocyte colony stimulating factor: adverse event reports filed with FDA
785 reports list it as a suspect or interacting product, 2005–2021. Also reported as Granulocyte Colony Stimulating Factor Nos.
- 785
- reports as suspect product
- 0% of all reports · about 37 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 98.6%
- marked serious by the reporter
- 57.4% across all reports
- 29.9%
- record death among outcomes, as reported
- 235 reports · not verified by FDA
785 adverse event reports received by FDA list granulocyte colony stimulating factor, a generic name as a suspect or interacting product, from June 2005 to September 2021. A further 1,555 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 37 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are febrile neutropenia (20.1%), product use in unapproved indication (13.1%) and mucosal inflammation (7.8%). A report can list several reactions, so shares add to more than 100%; 244 different terms appear across these reports. Febrile neutropenia is recorded in 20.1% of these reports, against 0.3% of all reports in the database.
98.6% of the reports are marked serious by the reporter; 29.9% record death among the outcomes and 18.2% record hospitalisation, as reported. 61.1% of the reports came from other health professionals, and the largest patient age group is 18 to 44 (13%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Granulocyte colony stimulating factor reports recording the termall reports in the database
- Febrile neutropeniafever with low white blood cells20.1%158
- Product use in unapproved indicationused for a purpose not on the label13.1%103
- Mucosal inflammation7.8%61
- Neutropenialow neutrophils, a type of white blood cell7.6%60
- Thrombocytopenialow platelets7%55
- Acute graft versus host disease6.6%52
- Sepsisa severe body-wide response to infection6.6%52
- Diarrhoealoose or frequent stools6%47
- Respiratory failurethe lungs could not supply enough oxygen5%39
- Pyrexiafever4.7%37
- Infectionan infection, type not specified4.2%33
- Disease progressionthe disease advanced3.9%31
- Off label useused for a purpose or in a way not on the label3.9%31
- Human herpesvirus 6 infection3.8%30
- Anaemialow red blood cells3.6%28
- Pneumonialung infection3.4%27
- Deaththe patient died; cause not stated by this term3.2%25
- Drug ineffectivethe medicine did not work as expected3.2%25
- Progressive multifocal leukoencephalopathyPML, a rare brain infection2.9%23
- Bone marrow failure2.8%22
- Meningitis tuberculous2.8%22
- Alanine aminotransferase increasedraised liver enzyme (ALT)2.7%21
- Platelet count decreasedlow platelet count2.5%20
- Engraftment syndrome2.4%19
- Herpes simplexa cold sore or genital herpes2.4%19
- Respiratory disorder2.4%19
- Cytomegalovirus viraemia2.3%18
- Decreased appetitereduced appetite2.3%18
Top 30 of 244 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 28% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Acute myeloid leukaemia | 110 | 14% |
| Prophylaxis | 75 | 9.6% |
| Neutropenia | 67 | 8.5% |
| Acute lymphocytic leukaemia | 37 | 4.7% |
| Bone marrow conditioning regimen | 37 | 4.7% |
| Haematopoietic stem cell mobilisation | 27 | 3.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 785 reports.
In context
| Measure | Granulocyte colony stimulating factor | All reports |
|---|---|---|
| Reports as suspect product | 785 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 98.6% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 299 | 91 |
| Hospitalisation recorded, per 1,000 reports | 182 | 213 |
| Consumer-filed share | 6.5% | 45.8% |
| Top term, share of reports | Febrile neutropenia 20.1% | 0.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Granulocyte colony stimulating factor reports
How many adverse event reports has FDA received for Granulocyte colony stimulating factor?
785 reports list Granulocyte colony stimulating factor as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 1,555 list it only as a concomitant medication.
What reactions are recorded in Granulocyte colony stimulating factor reports?
febrile neutropenia (20.1%), product use in unapproved indication (13.1%), mucosal inflammation (7.8%), neutropenia (7.6%) and thrombocytopenia (7%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Granulocyte colony stimulating factor was responsible.
How serious are the reports?
98.6% are marked serious by the reporter. Among the outcomes recorded, 29.9% of reports include death and 18.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (61.1%), physician (31%) and consumer or non-health professional (6.5%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Granulocyte colony stimulating factor rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Granulocyte colony stimulating factor was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Granulocyte colony stimulating factor?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Granulocyte colony stimulating factor as a suspect or interacting product; reports listing it only as a concomitant medication (1,555) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.